Novel compounds

A compound represented by formula (I):

• wherein:
• R1 and R2 are different or the same and are:
• H;
• (C3-C7) cycloalkylcarbonyl;
• (C1-C6) alkyl, optionally substituted by one or more substituents selected from the group consisting of (C3-C7) cycloalkyl and (C5-C7) cycloalkenyl;
• (C1-C6) haloalkyl;
• (C3-C7) cycloalkyl;
• (C5-C7) cycloalkenyl;
• (C2-C6) alkenyl;
• or
• (C2-C6) alkynyl;
• or R1 and R2, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring represented by formula (r) fused to the phenyl moiety which bears groups —OR1 and —OR2, wherein asterisks indicate carbon atoms shared with the phenyl ring:
• each R3 is independently CN, NO2, CF3, or a halogen atom;
• k is zero or an integer ranging from 1 to 3;
• A is a saturated and monocyclic (C3-C7) heterocycloalkylene group;
• W is:
• [1]-(CH2)sC(O)-[2] wherein s is zero or 1;
• [1]-C(O)(CH2)j[2], wherein j is 1 or 2;
• [1]-SO2(CH2)t-[2] wherein t is zero, 1 or 2;
• [1]-(CH2)ySO2-[2] wherein y is 1 or 2;
• [1](CH2)f-[2] wherein f is 1 or 2;
• or
• [1]C(O)(CH2)2SO2-[2];
• wherein [1] and [2] indicate the points of attachment for group W with, respectively, ring A and the phenyl moiety;
• each R4 is hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NR5R6, —CN, or —NR7SO2R8, and wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group,
• R5 is hydrogen or (C1-C6) alkyl;
• R6 is hydrogen or (C1-C6) alkyl;
• R7 is hydrogen or (C1-C6) alkyl;
• R8 is hydrogen or (C1-C6) alkyl;
• m is an integer ranging from 1 to 3;
• B is selected from:
• a group represented by formula (a) wherein the asterisk indicates the point of attachment for group B to the phenyl ring:
• wherein
• p is zero or 1;
• q is zero or 1;
• each R9 is independently halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NR10R11, —CN, or —NR12SO2R13, and wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group,
• R10 is hydrogen or (C1-C6) alkyl;
• R11 is hydrogen or (C1-C6) alkyl;
• R12 is hydrogen or (C1-C6) alkyl;
• R13 is hydrogen or (C1-C6) alkyl;
• n is an integer ranging from 1 to 3;
• E is a nitrogen containing group which is:
• a group (c) which is —(CH2)g—NR14R15 wherein g is an integer ranging from 1 to 4 and R14 and R15 are independently hydrogen or (C1-C4) alkyl;
• or
• a group (d) which is a saturated monocyclic or bicyclic or tricyclic heterocyclic ring system optionally substituted by one or two groups R16 which are at each occurrence are independently (C1-C4) alkyl or benzyl;
• a group of formula (b) wherein the asterisk indicates the point of attachment for group B to the phenyl ring:
• wherein
• R17 is hydrogen, (C1-C4) alkyl, or —SO2(C1-C4)alkyl;
• R18 is an aryl group or a 5 to 11 membered heteroaryl group, wherein said aryl group and said heteroaryl group are optionally substituted by 1 to 3 groups R19;
• R19 is at each occurrence independently halogen, (C1-C4)haloalkyl, hydroxy, —SO2NR20R21, —CN, —NR22SO2R23, (C1-C4) alkyl, or (C1-C4) alkoxy wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl group, and wherein
• R20 is hydrogen or (C1-C6) alkyl;
• R21 is hydrogen or (C1-C6) alkyl;
• R22 is hydrogen or (C1-C6) alkyl;
• R23 is hydrogen or (C1-C6) alkyl;
• Z is a bond or a divalent radical which is —(CH2)—, —(CH2)2—, —S—, —S(O)—, —S(O2)—, —C(O)—, or a group [5]-(C1-C4)alkylOC(O)-[6], wherein [5] and [6] represent, respectively the point of attachment of group Z to the phenyl ring and to the nitrogen atom;
• and
• E is a group as above defined
• or an N-oxide on the pyridine ring, or a pharmaceutically acceptable salt thereof.